OSDDMalaria:OSDD Malaria Meeting Sydney 2012

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Tech Ops        FAQ       

Open Source Drug Discovery for Malaria - February 24th 2012

There will be a one-day meeting on Open Source Drug Discovery for Malaria at The University of Sydney, February 2012.

Location Information

The meeting will take place on the main Camperdown campus of The University of Sydney.

Schedule

9 a.m. start Welcome by Mat Todd and opening remarks by Mary O'Kane, NSW Chief Scientist.
Morning session 1: What is the current status of drug discovery and development (with some focus on malaria)? Sessions to be led by Mary Moran and Luigi Palombi.
11 - Coffee
Morning session 2: What is the scientific and economic case for open source drug discovery? Mat Todd and his team will describe what open science is, and how it can be done. Richard Jefferson will demo the patent lens.
1-2 Lunch
Afternoon session 1: What are the most significant types of drugs needed for the treatment of malaria? Paul Willis will lead a survey of current treatments.
3:30-4 Break
Afternoon session 2: Which compounds should we pursue? Who should do it? How?
5 p.m. Drinks and dinner

Sessions will broadly address these questions:

General:

• How is it best to share chemical and biological data in an open project?
• What technical barriers prevent open science?
• Which licence governs an open source drug discovery project?
• What psychological/professional barriers are there to open science?
• Is there a danger that open source drug discovery can be hijacked by people taking all the data and patenting them?
• Who might participate?
• Who will fund later stages such as clinical trials?
• Who will manufacture open drugs?

Malaria-specific:

• Is the GSK arylpyrrole set the best set of compounds to start with?
• What other compounds are promising starting point? Who might want to work on those compounds?
• For hit-to-lead, what data are typically needed, and from which assays? What criteria do we apply to compounds as they progress through such assays?
• Do we only want to look at compounds with both blood and liver stage activity? (e.g. those in recent Novartis screen) How can we access liver stage viability assays?
• Do we want compounds with cross-species activity, e.g. HAT/Chagas. Can we mine this information from e.g. Chembl?

To suggest questions/sessions of interest, please modify this page directly (getting an OWW account is very easy) or contact Mat Todd.

Attending

• Mat Todd, University of Sydney
• Mary O'Kane, NSW Chief Scientist
• Luigi Palombi, Centre for Governance of Knowledge and Development, ANU, Canberra
• Paul Willis, MMV, Geneva
• Saman Habib, CDRI, Lucknow, India
• Stuart Ralph, Bio21, University of Melbourne
• Paul Ylioja, University of Sydney
• Murray Robertson, University of Sydney
• Neil Saunders, Bioinformatician, CSIRO
• Mary Moran, Policy Cures
• Nico Adams, CSIRO
• Andrew Treloar, Australian National Data Service
• Richard Jefferson, CAMBIA
• Nick Hunt, The University of Sydney

Invited

• Alastair Robertson, CSIRO
• Richard Head, CSIRO
• Michelle Gatton
• Hazel Moir
• Vicky Avery, Discovery Biology, Griffith University

Potential Invitees

Possibly interesting list maintained here

• Danah Boyd
• Rowena Martin
• Don McManus
• Kiaran Kirk
• Anna George
• Someone from Transparency Life Sciences